Am Rev Respir Dis
"When we have incidents like weve had in the last few days where questions get raised as a result of those, that you cant defend, weve had to make a decision to end the partnership," he said
PMID: 6928106
In one multicenter study, GLP-1 medicine use was associated with lower risks of major heart events, blood clots, kidney disease progression, and death compared with DPP-4 inhibitor medicines in patients with lupus and type 2 diabetes
Overweight Individuals with Health Conditions: People with a BMI of 27 or higher who also have weight-related health issues, such as type 2 diabetes, hypertension, or high cholesterol, can benefit from GLP-1 shots
Semaglutide (Wegovy): Clinical Evidence Semaglutide, marketed as Wegovy for weight management, has been the most extensively studied GLP-1 agonist for obesity treatment